3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
2
Terminated
1
Sponsor Class
INDUSTRY
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Conditions
Urinary Bladder Neoplasms
7
Peritoneal Neoplasms
4
Non-Muscle Invasive Bladder Neoplasms
4
Colorectal Neoplasms
3
Carcinoma, Transitional Cell
3
Appendiceal Neoplasms
3
Urologic Neoplasms
2
Urogenital Neoplasms
2
Stomach Neoplasms
2
Recurrence
2
Pseudomyxoma Peritonei
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasms
2
Anus Neoplasms
2
Uterine Neoplasms
1
Urologic Diseases
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Sarcoma
1
Pleural Neoplasms
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Necrosis
1
Mediastinal Neoplasms
1
Male Urogenital Diseases
1
Gastrointestinal Neoplasms
1
Female Urogenital Diseases
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cisplatin
4
atezolizumab
3
Nivolumab
3
Carboplatin
3
pembrolizumab
2
entrectinib
2
cobimetinib
2
capmatinib
2
alectinib
2
abemaciclib
2
Vemurafenib
2
Radiosurgery
2
Pemetrexed
2
Mitomycin
2
Fulvestrant
2
Drug Therapy
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
spartalizumab
1
ribociclib
1
repotrectinib
1
relatlimab
1
relacorilant
1
pertuzumab
1
palbociclib
1
olaparib
1
lutetium Lu 177 dotatate
1
exemestane
1
enzalutamide
1
enfortumab vedotin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms by Site
×
Mitomycin
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled
NCT05874921
2025-02-28
uTRACT
UroGen Pharma Ltd.
Recruiting
400 enrolled